Provectus Biopharmaceuticals Current Cash

Provectus Biopharmaceuticals (PVCT) currently reports a current cash of $220K as of March 2026. That compares with $390K in the prior-year period — down 42.7% year over year. Use the charts on this page to explore Provectus Biopharmaceuticals's current cash history and peer comparisons.

Provectus Biopharmaceuticals's current cash decreased from $390K to $220K — a 42.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Provectus Biopharmaceuticals reported $220K in current cash as of March 2026. That compares with $390K in the prior-year period — down 42.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $220K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Provectus Biopharmaceuticals, and consider following PVCT for alerts when major investors trade the stock.

Provectus Biopharmaceuticals is classified in the Healthcare sector. On current cash, it currently shows $220K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PVCT with unrelated industries.